Harnessing the antibacterial and immunological properties of mucosal-associated invariant T cells in the development of novel oral vaccines against enteric infections
Open Access
- 1 November 2014
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 92 (2) , 173-183
Abstract
No abstract availableKeywords
This publication has 79 references indexed in Scilit:
- The molecular basis for Mucosal-Associated Invariant T cell recognition of MR1 proteinsProceedings of the National Academy of Sciences, 2013
- Polyclonal Mucosa-Associated Invariant T Cells Have Unique Innate Functions in Bacterial InfectionInfection and Immunity, 2012
- Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000The Lancet, 2012
- Detection of prokaryotic mRNA signifies microbial viability and promotes immunityNature, 2011
- Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17–secreting T cellsBlood, 2011
- Antimicrobial activity of mucosal-associated invariant T cellsNature Immunology, 2010
- Lipid and glycolipid antigens of CD1d-restricted natural killer T cellsSeminars in Immunology, 2010
- Stepwise Development of MAIT Cells in Mouse and HumanPLOS Biology, 2009
- CD1d-restricted iNKT cells, the ‘Swiss-Army knife’ of the immune systemCurrent Opinion in Immunology, 2008
- MR1 uses an endocytic pathway to activate mucosal-associated invariant T cellsJournal of Experimental Medicine, 2008